Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P42285

UPID:
MTREX_HUMAN

ALTERNATIVE NAMES:
ATP-dependent RNA helicase DOB1; ATP-dependent RNA helicase SKIV2L2; Superkiller viralicidic activity 2-like 2; TRAMP-like complex helicase

ALTERNATIVE UPACC:
P42285; Q2M386; Q6MZZ8; Q6P170; Q8N5R0; Q8TAG2

BACKGROUND:
The Exosome RNA helicase MTR4, known for its ATP-dependent RNA unwinding activity, is integral to the RNA exosome's function in degrading nuclear RNA. It is associated with various complexes like TRAMP-like, NEXT, and PAXT, targeting a wide range of RNAs for degradation. This helicase's activity is fundamental in maintaining RNA homeostasis and processing pre-mRNA and rRNA.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Exosome RNA helicase MTR4 offers a promising avenue for developing novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.